Abbott to buy Chile’s CFR for $3bn


US medical products specialist Abbott has agreed to buy Chilean generic drugmaker CFR Pharmaceuticals for $2.9 billion (£1.7 billion), and will take on $430 million of CFR’s debt.

The move will bolster Abbott’s position in the rapidly growing markets of Latin America, expanding the company by around 7000 employees at R&D and manufacturing facilities in Chile, Colombia, Peru and Argentina. Abbott will also get access to CFR’s portfolio of over 1000 branded generic drugs and other products, as well as its distribution networks across the region.


Related Content

Medical devices consolidation continues

4 February 2016 Business

news image

Abbott to buy Alere for $5.8bn to augment its point-of-care diagnostics business

PPG to buy Mexican paints firm Comex

1 July 2014 Business

news image

$2.3bn deal expands US firm’s footprint in Central America

Most Commented

New law on legal highs approved in UK

1 February 2016 News and Analysis

news image

A blanket ban on New Psychoactive Substances has been given final approval and will come into force in April

Beyond element 118: the next row of the periodic table

29 January 2016 News and Analysis

news image

A technological leap may be called for to expand the number of elements in existence